Patent application number | Description | Published |
20090007822 | Electrostatically-Applicable, Heat-Fusable Powder Coatings and Additives - Coatings for metal substrate surfaces comprise at least one film forming polymer is combined with microfine, substantially moisture-free cementitious particles. Preferred methods involve fusion bonded coating applications, wherein dry powder blends comprising polymer and the cementitious particles which preferably containing a corrosion inhibiting agent are electrostatically applied and heat-fused onto the metal. | 01-08-2009 |
20100310846 | CEMENTITIOUS FOAMS AND FOAM SLURRIES - Lightweight cementitious foams of the invention have excellent dynamic and dimensional stability due to use of foaming system comprising polycarboxylate surfactant foam generating agent, foam stabilizer (e.g., PVOH), and shrinkage reducing admixture to inhibit plastic shrinkage and micro-cracking of cement. The foaming system can be used in conventional cement mortars or concretes as well as with exemplary cementitious slurry systems of the invention, which include an expansive agent, a cross-linking agent for the foam stabilizer. Microfibers can be used in the foam, slurry, or both, to prevent micro-cracking. Cementitious foams can be made without use of autoclave or lightweight aggregates to achieve enhanced compressive strength and thermal insulation properties that compare favorably with conventional foams and insulation materials at comparable densities. | 12-09-2010 |
20120231170 | VAPOR PERMEABLE BARRIER COATING APPLICABLE AT LOW TEMPERATURE - Disclosed is a coating composition that includes an aqueous emulsion of a hydrophobic acrylic polymer, a water-soluble polymer, and an inorganic filler, and further includes a freezing-point lowering component to permit low temperature application. The freezing-point lowering component will preferably include a water-soluble, corrosion inhibiting salt. The coating composition will also optionally and preferably include an evaporation enhancing component to promote faster drying and skin formation at low temperatures. The coating composition may be coated onto a construction surface (e.g., by spraying) where, after drying, it will form a fully adhered barrier membrane that is water-vapor permeable, but air and liquid-water impermeable. Such membrane will preferably have sufficient coating thickness and sufficiently high elongation that it will bridge joints and cracks. | 09-13-2012 |
20120322902 | CEMENTITIOUS FOAM COMPOSITIONS - Lightweight cementitious foams of the invention have excellent dynamic and dimensional stability due to use of foaming system comprising polycarboxylate surfactant foam generating agent, foam stabilizer (e.g., PVOH), and shrinkage reducing admixture to inhibit plastic shrinkage and micro-cracking of cement. The foaming system can be used in conventional cement mortars or concretes as well as with exemplary cementitious slurry systems of the invention, which include an expansive agent, a cross-linking agent for the foam stabilizer. Microfibers can be used in the foam, slurry, or both, to prevent micro-cracking. Cementitious foams can be made without use of autoclave or lightweight aggregates to achieve enhanced compressive strength and thermal insulation properties that compare favorably with conventional foams and insulation materials at comparable densities. | 12-20-2012 |
Patent application number | Description | Published |
20090074760 | USE OF CHIMERIC ANTI-CD20 ANTIBODY AS IN VITRO OR IN VIVO PURGING AGENT IN PATIENTS RECEIVING BMT OR PBSC TRANSPLANT - The use of anti-CD20 antibodies as in vivo purging agents for patients receiving bone marrow or peripheral blood stem cell transplant during treatment of B-cell-related diseases, e.g., B-cell lymphomas or leukemias, is disclosed. Such purging may enhance engraftment and/or prevent disease relapse in such patients. | 03-19-2009 |
20100080769 | Treatment of Chronic Lymphocytic Leukemia using Anti-CD20 Antibodies - Chronic Lymphocytic Leukemia (CLL) may be treated with antibodies directed against the CD20 antigen. | 04-01-2010 |
20110008250 | Treatment of Autoimmune Diseases - The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20. | 01-13-2011 |
20110008336 | Treatment of Autoimmune Diseases - The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20. | 01-13-2011 |
20110008337 | Treatment of Autoimmune Diseases - The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20. | 01-13-2011 |
20110008338 | Treatment of Autoimmune Diseases - The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20. | 01-13-2011 |
20120201818 | TREATMENT OF MULTIPLE SCLEROSIS - The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20. | 08-09-2012 |
20130084289 | TREATMENT OF MULTIPLE SCLEROSIS - The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20. | 04-04-2013 |
20130273039 | COMBINATION THERAPIES FOR B-CELL LYMPHOMAS COMPRISING ADMINISTRATION OF ANTI-CD20 ANTIBODY - New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise, in particular, administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkin's lymphomas. | 10-17-2013 |
20130273041 | USE OF CHIMERIC ANTI-CD20 ANTIBODY AS IN VITRO OR IN VIVO PURGING AGENT IN PATIENTS RECEIVING BMT OR PBSC TRANSPLANT - The use of anti-CD20 antibodies as in vivo purging agents for patients receiving bone marrow or peripheral blood stem cell transplant during treatment of B-cell-related diseases, e.g., B-cell lymphomas or leukemias, is disclosed. Such purging may enhance engraftment and/or prevent disease relapse in such patients. | 10-17-2013 |
20130273042 | TREATMENT OF MULTIPLE SCLEROSIS - The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20. | 10-17-2013 |
20140030263 | TREATMENT OF DIFFUSE LARGE-CELL LYMPHOMA WITH ANTI-CD20 ANTIBODY - The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen. | 01-30-2014 |
20140056887 | COMBINATION THERAPIES FOR B-CELL LYMPHOMAS COMPRISING ADMINISTRATION OF ANTI-CD20 ANTIBODY - New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise, in particular, administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkin's lymphomas. | 02-27-2014 |
20140134164 | TREATMENT OF MULTIPLE SCLEROSIS - The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20. | 05-15-2014 |
20140302018 | TREATMENT OF DIFFUSE LARGE-CELL LYMPHOMA WITH ANTI-CD20 ANTIBODY - The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen. | 10-09-2014 |
20140363424 | USE OF CHIMERIC ANTI-CD20 ANTIBODY AS IN VITRO OR IN VIVO PURGING AGENT IN PATIENTS RECEIVING BMT OR PBSC TRANSPLANT - The use of anti-CD | 12-11-2014 |